

ACURA PHARMACEUTICALS, INC
Form 8-K
March 02, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934**

March 2, 2015

Date of Report (Date of earliest event reported)

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

State of New York	1-10113	11-0853640
(State of Other Jurisdiction (Commission File Number of Incorporation)	(I.R.S. Employer Identification Number)	

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

(847) 705-7709

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-J(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-L(c))

Item 2.02 Results of Operations and Financial Condition

On March 2, 2015 we issued a press release disclosing the financial results for our fourth quarter ended December 31, 2014 and our fiscal year ended December 31, 2014. A copy of our press release is being furnished as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits

Exhibit Number Description

<u>99.1</u>	<u>Press Release dated March 2, 2015 announcing financial results for the fourth quarter ended December 31, 2014 and the fiscal year ended December 31, 2014</u>
-------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A. Clemens
Peter A. Clemens
Senior Vice President & Chief Financial Officer

Date: March 2, 2015

Exhibit Index

Exhibit Number **Description**

<u>99.1</u>	<u>Press Release dated March 2, 2015 announcing financial results for the fourth quarter ended December 31, 2014 and the fiscal year ended December 31, 2014</u>
-------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------